S&P Futures
4,319.75 +2.00 (+0.05%) Dow Futures
34,015.00 -28.00 (-0.08%) Nasdaq Futures
14,054.00 +67.25 (+0.48%) Russell 2000 Futures
1,915.10 -13.20 (-0.68%) Crude Oil
87.15 +0.54 (+0.62%) Gold
1,792.40 -2.60 (-0.14%)
Rubius Therapeutics, Inc. (RUBY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.96 |
| Open | 7.01 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1200 |
| Day's Range | 6.34 - 7.01 |
| 52 Week Range | 6.34 - 38.71 |
| Volume | |
| Avg. Volume | 466,080 |
| Market Cap | 575.141M |
| Beta (5Y Monthly) | 2.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.50 |
- GlobeNewswire
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune disease, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advance
- GlobeNewswire
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference
Continuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Expected in Q1’22 Initial Clinical Results Expected from the Phase 1 Clinical Trial of RTX-321 in HPV 16-Positive Cancers During and the RTX-240 Phase 1 Combination Clinical Trial with Pembrolizumab in 2H’22 First Patient Expected to be Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with S
- GlobeNewswire
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12
